Biology-Directed Therapy for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangements

Vivian G Oehler^{1

2}, Roland B Walter^{1

2

3}

Affiliations

¹ Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle.
² Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle.
³ Department of Laboratory Medicine and Pathology, University of Washington, Seattle.

Editorial

Vivian G Oehler et al. NEJM Evid. 2025 Sep.

. 2025 Sep;4(9):EVIDe2500196.

doi: 10.1056/EVIDe2500196. Epub 2025 Aug 26.

Vivian G Oehler^{1

2}, Roland B Walter^{1

2

3}

¹ Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle.
² Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle.
³ Department of Laboratory Medicine and Pathology, University of Washington, Seattle.

No abstract available

Comment on

Ertugliflozin to Reduce Arrhythmic Burden in Patients with ICDs/CRT-Ds.
Benedikt M, Oulhaj A, Rohrer U, Manninger M, Tripolt NJ, Pferschy PN, Aziz F, Wallner M, Kolesnik E, Gwechenberger M, Martinek M, Nürnberg M, Roithinger FX, Steinwender C, Widkal J, Leiter S, Zirlik A, Stühlinger M, Scherr D, Sourij H, von Lewinski D. Benedikt M, et al. NEJM Evid. 2024 Oct;3(10):EVIDoa2400147. doi: 10.1056/EVIDoa2400147. Epub 2024 Sep 1. NEJM Evid. 2024. PMID: 39217453 Clinical Trial.